Mirum Pharmaceuticals Inc
08D
Company Profile
Business description
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Contact
989 East Hillsdale Boulevard
Suite 300
Foster CityCA94404
USAT: +1 650 667-4085
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
418
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.50 | 10.90 | -0.12% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 24,994.83 | 254.47 | 1.03% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 22,725.56 | 351.35 | -1.52% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 69,133.56 | 3,232.78 | -4.47% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,755.60 | 8.40 | -0.10% |
| SSE Composite Index | 4,065.79 | 54.49 | -1.32% |